Adagene (ADAG) will host a virtual key opinion leader event on Saturday, January 25, 2025 at 1:00 PM ET, featuring Aurelien Marabelle, MD, PhD, ...

Hanx Biopharma begins patient dosing in Australia for phase 1 trial of HX044 to treat advanced solid tumours: Wuhan, China Saturday, January 4, 2025, 16:00 Hrs [IST] Hanx Biopharm ...

SHANGHAI, Dec. 22, 2024 /PRNewswire/ -- CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, ...

近日，德国弗赖堡大学研究团队在Nature Immunology期刊发表的最新研究成果就显示，CTLA-4抑制剂与PD-1抑制剂联合使用时，能让T细胞响应联合治疗的关键 ...

在全球医疗行业瞩目的第43届摩根大通医疗健康年会（J.P. Morgan Healthcare Conference，简称JPM大会）上，舜景医药创新性的双特异性抗体SGT003惊艳亮相，向世界展现了生物创新药的“中国方案”，获得与会各方广泛关注。

智通财经APP获悉，基石药业(02616)今日宣布，公司用于治疗多种实体瘤的管线2.0重磅产品CS2009（PD-1/VEGF/CTLA-4三特异性抗体）已 ...

1Northwestern University, Chicago, Illinois.

Faming Zhang, Chairman of Hanx Biopharmaceuticals. "HX044 is a next generation CTLA-4 bispecific antibody fully developed in-house by the company, starting from molecule design. It enhances ...